Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Bardelli

Showing results (191-200 of 281) with videos related to

Pageof 29
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2023
Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal CancerGiorgio Patelli, Gianluca Mauri, Federica Tosi, et al.
Molecular Oncology|May 23, 2025
TRPM8 levels determine tumor vulnerability to channel agonistsAlessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, et al.
Genome Medicine|June 30, 2019
Evolving neoantigen profiles in colorectal cancers with DNA repair defectsGiuseppe Rospo, Annalisa Lorenzato, Nabil Amirouchene-Angelozzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancerFrancesca Molinari, Lara Felicioni, Michela Buscarino, et al.
Plos One|May 10, 2012
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodesJeffrey J Wallin, Jane Guan, Kyle A Edgar, et al.
EMBO Molecular Medicine|May 19, 2026
WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancerKristi Buzo, Laura Bizzozero, Marilena Lentini, et al.
Cancer Discovery|October 4, 2015
Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric CancerEunice L Kwak, Leanne G Ahronian, Giulia Siravegna, et al.
JAMA|October 28, 2010
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximabWendy De Roock, Derek J Jonker, Federica Di Nicolantonio, et al.
Cell Death & Disease|October 30, 2020
RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancerHajrah Khawaja, Andrew Campbell, Jamie Z Roberts, et al.
Neuro-Oncology|February 11, 2014
The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT aloneRemco J Molenaar, Dagmar Verbaan, Simona Lamba, et al.
Pageof 29

Showing results (191-200 of 281) with videos related to

Sort By:
Pageof 29
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2023
Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal CancerGiorgio Patelli, Gianluca Mauri, Federica Tosi, et al.
Molecular Oncology|May 23, 2025
TRPM8 levels determine tumor vulnerability to channel agonistsAlessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, et al.
Genome Medicine|June 30, 2019
Evolving neoantigen profiles in colorectal cancers with DNA repair defectsGiuseppe Rospo, Annalisa Lorenzato, Nabil Amirouchene-Angelozzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancerFrancesca Molinari, Lara Felicioni, Michela Buscarino, et al.
Plos One|May 10, 2012
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodesJeffrey J Wallin, Jane Guan, Kyle A Edgar, et al.
EMBO Molecular Medicine|May 19, 2026
WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancerKristi Buzo, Laura Bizzozero, Marilena Lentini, et al.
Cancer Discovery|October 4, 2015
Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric CancerEunice L Kwak, Leanne G Ahronian, Giulia Siravegna, et al.
JAMA|October 28, 2010
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximabWendy De Roock, Derek J Jonker, Federica Di Nicolantonio, et al.
Cell Death & Disease|October 30, 2020
RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancerHajrah Khawaja, Andrew Campbell, Jamie Z Roberts, et al.
Neuro-Oncology|February 11, 2014
The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT aloneRemco J Molenaar, Dagmar Verbaan, Simona Lamba, et al.
Pageof 29